BIVI$1.71+24.82%
Biovie Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$14.59M
Float & O/S:
Inst Own:
DilutionScan read 17 of BIOVIE INC.'s SEC filings and found 18 warrant series, 1 convertible, 2 ATM programs, 2 shelf registrations, 3 S-1 registrations and 2 completed offerings on file for BIVI. The latest dilution event on file is ATM sales on Sep 11, 2026. Analysis updated Sep 17, 2026.
Signal8 Summary
3h old
BIVI
Going-concern warning, cash critically low
- Business
- WeakNo revenue, $22.1M net loss, going-concern warning
- Stock risk
- High$12.1M micro-cap, shares +390% YoY, 134% dilution overhang
Snapshot
BioVie is a clinical-stage biotech with no revenue, testing bezisterim in Parkinson's, Alzheimer's and Long COVID, plus a cirrhosis drug in earlier testing.
What's Happening Right Now
- : On Nov 2, 2026, BioVie was invited to give a late-breaking presentation on bezisterim Long COVID data in Nice, France; the company's own disclosure notes the trial missed statistical significance in the overall patient population, with gains limited to pre-specified high-symptom subgroups.
- : BioVie was invited to present ADDRESS-LC Long COVID data at an NIH RECOVER-TLC workshop on Nov 5, 2026, again noting the overall trial population missed significance on all endpoints while pre-specified subgroups showed significant gains.
- : On Oct 20, 2026, BioVie presented Phase 2b SUNRISE-PD results at the American Neurological Association meeting showing bezisterim significantly improved motor and non-motor symptoms in a high-inflammation subgroup of the 57-patient trial, a result the company calls exploratory ahead of a larger confirmatory trial.
- : On Oct 19, 2026, BioVie reported that bezisterim's Long COVID benefits were concentrated in patients with severe baseline fatigue, PEM or cognitive impairment, with the overall intent-to-treat population only trending toward improvement in the 203-patient ADDRESS-LC trial.
- : On Sep 11, 2026, BioVie set up an at-the-market program to sell up to $6.46M of stock through A.G.P./Alliance Global Partners, disclosing that full use could add roughly 3.1 million shares to the then-8.53 million outstanding and flagging substantial-dilution and Nasdaq delisting risk.
- : Registered 16.03M shares for sale on Form S-1.
- : Registered $300.00M of securities for sale on Form S-3.
- : Raised $12.00M in gross proceeds through a public offering, with warrants over 7.35M shares.
